This is the authors' abstract. We don't add key points for this paper.
OBJECTIVE: Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet the burden of disease is significant. We report on a pivotal safety study of the first tubeless, on-body automated insulin delivery system with customizable glycemic targets. RESEARCH DESIGN AND METHODS: and percent time in sensor glucose range 70-180 mg/dL ("time in range"). There were three severe hypoglycemia events not attributable to automated insulin delivery malfunction and one diabetic ketoacidosis event from an infusion site failure. CONCLUSIONS: levels and time in target glucose range with a very low occurrence of hypoglycemia.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: